SUPPLEMENTARY FIG. S3. Effects of MitoTEMPO treatment in aged *Apoe*[−/−] **mice. (A)** Representative aortic sinus sections were stained for immunoreactive NOX4. Immunohistochemistry scoring of NOX4 levels (mean ± SEM, $n = 8$). Scale is 100 μm. **(B)** LVEF, LVEDV, LVPWT, and calculated LV mass were determined by echocardiography and are presented as mean ± SEM ($n = 8$). **(C)** Plasma cholesterol and triglyceride levels (mean ± SEM, $n = 8$). **(D)** Plasma ALT, CK, and BUN levels (mean ± SEM, $n = 8$). **(E)** Representative images of H&E-stained liver sections. Scale is 100 μm. **(F)** Representative images of H&E-stained kidney sections. Scale is 100 μm. ALT, alanine aminotransferase; BUN, blood urea nitrogen; CK, creatine kinase; H&E, hematoxylin and eosin; LV mass, left ventricle mass; LVEDV, left ventricle end-diastolic volume; LVEF, left ventricle ejection fraction; LVPWT, left ventricle posterior wall thickness; MitoTEMPO, (2-(2,2,6,6-tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride; SEM, standard error of the mean.